Background Nitric oxide (NO) is a compound with both protective and damaging effects on neurons. Quantification of NO metabolites in humans is limited by sample contamination with blood. In vivo cerebral microdialysis may offer an alternative approach as sampling of extracellular fluid (ECF) adjacent to neurons becomes possible. We investigate the prognostic value of brain ECF NO metabolites in patients with traumatic brain injury (TBI). Methods A prospective case cohort of 195 ECF samples collected from 11 cases over 4 days following TBI was collected. Nitrate and nitrite concentrations ([NO x ]) were quantified using a vanadium-based colorimetric assay. Results Early ECF [NO x ] (<48 h post TBI) were significantly higher in non-survivors (median 59.2 lmol/l, n = 7) compared to survivors (23.3 lmol/l, n = 4) (P = 0.04). Late (48-96 h) ECF [NO x ] remained higher in non-survivors (47.9 lmol/l) compared to survivors (23.0 lmol/l) but this was not significant (P = 0.29).
Introduction
Nitric oxide (NO) is a free radical involved in diverse physiological and pathophysiological processes in the central nervous system. After traumatic brain injury (TBI), NO may have both protective and damaging effects [1] and this relates to NO's role in cerebral blood flow regulation [2] , its reaction with superoxide to form peroxynitrite, and its inhibition of cytochrome c oxidase [3] . TBI remains the major cause of death in young people and survival of TBI is associated with significant morbidity. Improved prognostication after TBI might facilitate patient selection for aggressive management strategies, which may improve mortality but carry the risk of increased morbidity if patient selection is suboptimal.
Owing to its short half-life, it is difficult to measure nitric oxide concentration directly, but measurement of the concentration of downstream NO metabolites, nitrate and nitrite (NO x ), is an accepted method of estimating endogenous NO production [4] . NO x concentration ([NO x ]) in the cerebrospinal fluid (CSF) of patients after TBI has been reported [5, 6] but the presence of subarachnoid hemorrhage, as commonly occurs after TBI, can influence CSF [NO x ] measurement [4] and might reduce the usefulness of CSF [NO x ] as a marker of secondary injury.
Cerebral microdialysis is an established technique that allows focal measurement of brain extracellular fluid (ECF) biochemistry [7, 8] . As the microdialysis catheter is placed in brain tissue, it can be used to assess [NO x ] closer to NO's site of action than that measured in CSF and localize the measurement to a particular area of interest. Microdialysate [NO x ] in the brains of rats post cortical impact injury correlates well with direct NO electrode readings [1] .
In this study, we measure the concentration of nitrite and nitrate in the brain extracellular fluid of patients with traumatic brain injury and relate it to patient outcome.
Materials and Methods

Patients and Sample Preparation
This study was approved by the Joint Research Ethics Committee of the National Hospital for Neurology and Neurosurgery and the Institute of Neurology and, as all patients were unconscious at the time of the study, written assent was obtained from their personal representatives.
We studied eleven adults with TBI undergoing protocolised management to control cerebral perfusion pressure (CPP) and intracranial pressure (ICP) on the neurocritical care unit. The patients were all male with median age 26.5 years (range 17-68). As part of routine clinical monitoring of brain ECF biochemistry each patient had a commercially available microdialysis catheter (CMA 70, CMA/Microdialysis, Solna, Sweden) with a 10 mm dialysis membrane length and 20 kDa molecular weight cut-off inserted into their brain tissue through a skull bolt (Technicam Ltd, Newton Abbott, UK). Probe positioning followed the recommendations of the consensus meeting on microdialysis in neurointensive care [9] . The probe was perfused with artificial CSF (Perfusion Fluid CNS, CMA), using a CMA 106 pump, at a rate of 0.3 ll/min. Following consensus guidelines, the system was allowed to equilibrate for 1 h prior to starting microdialysate sample collection [9] .
Systemic data including CCP and ICP were collected electronically after every hour of sampling. After routine measurement of standard microdialysis variables, including lactate:pyruvate ratio (LPR), using the CMA 600 analyser (CMA/Microdialysis, Solna, Sweden), the microdialysate samples were stored immediately at -80°C prior to NO x assay.
Microdialysate sampling was continued until invasive intracranial monitoring was no longer clinically indicated and at that stage the microdialysis catheter was removed. In any event only samples from the first 4 days post injury were included in this analysis. Peak CSF [NO x ] occurs within the first 48 h post TBI [5, 6] and so samples for analysis were divided into those taken up to 48 h, and those taken 48-96 h, post TBI.
We used a vanadium-based assay for nitrite/nitrate measurement in biological specimens as described by Miranda et al. [10] . This assay has been validated for human body fluids and samples were prepared accordingly [4] .
Reagents
Sulfanilamide (SULF), N-(1-Napthyl) ethyl-enediamine dihydrochloride (NEDD), vanadium (III) chloride (VCI 3 ), sodium nitrite, sodium nitrate and hydrochloric acid were purchased from Sigma-Aldrich (Poole, Dorset, UK). Water was purified with Milli-RO and Millli-Q systems (Millipore).
The assay was performed in a standard flat-bottomed 96-well polystyrene microtitre plate, containing 50 ll/well of standard or sample in duplicate.
Immediately before commencing the assay, Griess reagents: SULF (50 ll) and NEDD (50 ll) were premixed and added to each well. Nitrite mixed with Griess reagents forms a chromophore from the diazotization of sulfanilamide by acidic nitrite followed by coupling with bicyclic amines such as N-1-(Napthyl) ethylenediamine. Subsequently, the vanadium solution was added in a volume of 100 ll/well, the contents mixed vigorously and the plate left to incubate for 60 min at 37°C. The absorbance at 540 nm was measured to assess the total level of (NO x ) in the samples.
Statistical Analysis
Data were analysed using SAS software (version 9.1, SAS Institute, Cary, NC, USA). Wilcoxon rank sum test was used to compare variables in survivors and non-survivors. The median and interquartile range data are presented. Receiver operator characteristic (ROC) analysis is used to determine the sensitivity and specificity of threshold variable values for non-survival. Multivariate analyses were performed for comparison of clinical phenotypes. Two tailed exact P values are presented throughout and values of less than 0.05 are considered significant.
Results
195 microdialysate samples were analysed from 11 patients. The median microdialysate [NO x ] <48 h post TBI was significantly higher in non-survivors (59. 2) lmol/l in survivors (n = 4) and 47.9 (37.6-60.6) lmol/l in non-survivors (n = 5) (P = 0.29) (Fig. 1) . There was no significant difference in microdialysate [NO x ] over time for either subgroup although there was a trend toward microdialysate [NO x ] increasing over time in survivors and decreasing over time in non-survivors.
For the period <48 h post TBI, ROC analysis revealed microdialysate [NO x ] >26.5 lmol/l predicted non-survival with sensitivity 100% and specificity 75% and the area under the curve was 0.89. For the period 48-96 h post TBI microdialysate [NO x ] >24.1 lmol/l predicted non-survival with sensitivity 100% and specificity 75% and the area under the curve was 0.75 (Fig. 2) .
Multivariate analysis did not show significant differences in ICP, CPP or microdialysate lactate pyruvate ratio between survivors and non-survivors for either time period.
Discussion
This prospective study shows that it is feasible to reliably quantify NO x from minute amounts of human ECF using a rapid and high throughput technique. The main finding of this study is that ECF NO x samples in the initial 48 h after TBI were of prognostic value. The data are in line with results from CSF [NO x ] in humans after TBI [5] . The main advantage of ECF [NO x ] when compared to CSF [NO x ] is that sample contamination with blood containing systemic NO x is less likely.
The potential of this measurement is suggested by the fact that we saw significant differences in microdialysate [NO x ] between the outcome groups in the period <48 h post TBI whilst finding no differences in other measured variables. ROC analysis indicates effective discrimination between survivors and non-survivors for microdialysate [NO x ] <48 h post TBI as indicated by the large area under the ROC plot. Interestingly this overlaps with the time interval of accelerated neuronal loss following TBI [8] .
Our results suggest that microdialysate [NO x ] might be a useful prognostic marker after TBI and that its prognostic value may be greatest early after injury, during the first 48 h in this study. This is important because if prognostication of patient outcome is to guide clinical decision making it must be possible to do so as soon as possible after TBI.
This study presents data from a small number of patients and the threshold value we suggest must therefore be viewed as a preliminary result. We present these results to demonstrate the prognostic potential of microdialysate [NO x ] and for evaluation in future studies. These microdialysate concentrations are dependent on the relative recovery of NO x and hence the microdialysis catheter type and perfusate flow rate and in this study we use standard methods [7] . Automatization of the colorimetric method [10] used should be possible and thus allow for high throughput bedside measurements of ECF NO x concentrations from much larger patient cohorts. The incidence of mortality after TBI in our cohort is high and we believe that this is related to our selection of patients for cerebral microdialysis monitoring. In our centre, patients in whom sedation is stopped shortly after admission following either conservative or surgical management are not monitored using cerebral microdialysis and this study cohort therefore represents the more severely injured end of the spectrum of our TBI admissions. Because microdialysis was used as part of the clinical management, the catheters were also removed at the same time as the ICP bolt, which on average was after 4 days. Therefore, no statistical meaningful analyses were possible on the few patients in whom samples were collected for a longer time period. We do not believe this invalidates the interpretation of our data-analyses because this study was focused on the acute phase after TBI: particularly the initial 48 h described in the pioneering work of Hlatky et al. [2, 11] .
Microdialysate [NO x ] has been previously correlated with regional cerebral blood flow in patients with TBI [2] . In the above study no significant correlation was found between microdialysate [NO x ] and neurological outcome, which is in apparent contrast with earlier results reported by the same group where the highest microdialysate [NO x ] in the first 5 days after TBI were found in patients surviving with moderate or severe disability as opposed to non-survivors or those making a good recovery, with nonsurvivors having lower microdialysate [NO x ] than survivors [11] . This seems to be at variance with our findings, perhaps reflecting the complexity of NO's neuroprotective and neurotoxic roles, although our results are more consistent with previous CSF studies [5] . There are methodological difference to be considered between this study and references [2, 11] . Hlatky et al. reduced the samples with vanadium and then detected nitrate and nitrite using a commercially available chemiluminescence assay (NO Analysis System; Antek Instruments, Houston, TX, U.S.A.) [2, 11] . This method does not correct for a preanalytical error caused by binding of systemic NO x to systemic proteins. The method used in this study is based on the same redox-reactions elegantly described by Miranda et al. [10] , but sample preparation also includes ultrafiltration (10 kDa molecular weight filter, 17,5009g for 60 min) as described by our in-house validation of the Miranda et al. assay [10] for human biological fluids [5] .
Animal and human studies suggest that the peak in NO occurring >6 h post TBI is primarily related to expression of inducible nitric oxide synthase (iNOS) [1] and, as none of our patients were studied <6 h post TBI, the elevated microdialysate [NO x ] we observed in non-survivors may also to be due to iNOS. Most studies suggest that NO produced by iNOS has detrimental effects and that inhibition of iNOS activity after TBI might have benefit [1] , although this is not universally accepted. The present findings are in line with the basic science literature.
We would like to stress that, as NO is required for a number of vital physiological functions, any future treatment aiming to completely block NO production or receptor binding is likely to have deleterious effects. However, combining ECF NO x levels with a validated biomarker for neurodegeneration (eNfH) [8] might allow determination of the in vivo concentration at which neurotoxicity occurs and thus help establish a target treatment threshold for NO x lowering strategies.
